NEWS
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune SA (NASDAQ: ACIU) will present three oral presentations at the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, showcasing its precision medicine pipeline for neurodegenerative diseases. The presentations will focus on:
1. [18F]ACI-19626, a first-in-class TDP-43-PET tracer
2. ACI-24.060, an active immunotherapy inducing anti-Abeta antibodies
3. morADC (Morphomer®-Antibody Drug Conjugates), a new class of neurodegenerative disease-fighting drugs
Additionally, a poster presentation will compare clinical endpoint progression rates in sporadic Alzheimer's disease and Down Syndrome-related Alzheimer's disease.
1. [18F]ACI-19626, a first-in-class TDP-43-PET tracer
2. ACI-24.060, an active immunotherapy inducing anti-Abeta antibodies
3. morADC (Morphomer®-Antibody Drug Conjugates), a new class of neurodegenerative disease-fighting drugs
Additionally, a poster presentation will compare clinical endpoint progression rates in sporadic Alzheimer's disease and Down Syndrome-related Alzheimer's disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1064Followers
65Following
7221Visitors
Follow